We report a case of autoimmune-like hepatitis, as defined by the modified criteria of the International Autoimmune Hepatitis Group, 1 that developed in a patient following unrelated BMT and was successfully treated using rituximab.
8
/kg nucleated marrow cells (0.5 Â 10 6 /kg CD34 þ cells) were infused. Tacrolimus (0.02 mg/kg/day) and short-term MTX (15 mg/m 2 on day 1, 10 mg/m 2 on days 3, 6 and 11) were employed as prophylaxis against GVHD. Engraftment of neutrophils was achieved on day 14. Complete chimerism of blood cells was confirmed by STR analysis on day 80. Acute GVHD was not observed. Tacrolimus was discontinued on day 85 and the patient was discharged on day 99 without any complications.
She was re-admitted to our hospital on day 135 with elevated liver enzymes (aspartate aminotransferase, 495 IU/L; alanine aminotransferase, 748 IU/L). She exhibited no signs of intestinal or skin GVHD. Serological tests for hepatitis A, B and C yielded negative results. No CMV, EBV or human herpesvirus 6 genomic DNA was detected from PBMCs by real-time PCR. Although her Ig level was relatively high (IgG, 1878 mg/dL), negative results were obtained for all available autoimmune markers (antinuclear Ab, anti-double-strand DNA Ab, anti-single-strand DNA Ab, anti-smooth muscle Ab, anti-mitochondrial Ab and anti-liver kidney microsomal-1 Ab). The patient was treated with tacrolimus based on a tentative diagnosis of hepatic GVHD. After 15 days of treatment, serum transaminases had decreased, whereas total bilirubin level was elevated to 7.5 mg/dL. I.v. methyl prednisolone (mPSL) therapy (2.0 mg/kg/day) was started soon after liver biopsy on day 151 (Figure 1a) .
The histological picture of the liver specimen, including immunostaining, revealed that eosinophil, CD138 þ plasmacytes and CD20 þ B-lymphocyte infiltration predominated in portal areas. Interlobular bile ducts were preserved and CD8 þ T-cells were less than in GVHD or viral infections. Portal mononuclear cells invaded the limiting plates surrounding lobules, leading to interface hepatitis in the periportal area. Lobular inflammation was modest and marked hepatocyte swelling (ballooning degeneration) was observed (Figures 1b-h ). These findings were rather more consistent with autoimmune hepatitis (AIH) than with classical hepatic GVHD. Drug-induced hepatitis was excluded because drug administration was not changed before and after the onset of disease, although eosinophilic infiltration might suggest it. As no Epstein-Barr-encoded RNA-positive cells were found in any of the cells analyzed, the possibility of post-transplant lymphoproliferative disorder was excluded. According to the modified criteria of the International Autoimmune Hepatitis Group, our patient was diagnosed with definite AIH, defined by a score 415 (the patient's score was 17). 1 Hepatic dysfunction improved with mPSL treatment and the dosage was gradually tapered. On day 178, mPSL was converted to oral prednisolone (PSL). When the dosage of PSL was tapered to a dose of 1.0 mg/kg/day, serum transaminases again began to increase. Even though we increased the dosage of PSL to 1.3 mg/kg/day and added oral mycophenolate mofetil at a dose of 30 mg/kg/day on day 191, hyperbilirubinemia could not be fully controlled.
The patient was then treated using rituximab (375 mg/m 2 every 2 weeks for six consecutive weeks), as liver dysfunction was steroid-dependent and the histological picture demonstrated infiltration of CD20 þ B-lymphocytes. After rituximab treatment, serum transaminases gradually decreased and PSL was tapered to 0.1 mg/kg/day. On day 313, the serum transaminases increased and she was again treated using rituximab. Ten days after the last rituximab treatment, another liver biopsy was performed. CD20 þ B-lymphocytes were not observed in the histological picture (Figure 1e) , and serum transaminases gradually improved and normalized. Although the steroid dose was tapered and stopped, her liver dysfunction did not recur.
AIH is an immune-mediated necroinflammatory condition of the liver. Presentation can vary from the asymptomatic individual with abnormal liver function tests to fulminant liver failure. The diagnosis is based on the combination of biochemical, autoimmune and histological parameters, and the exclusion of other causes of liver diseases. We summarized occasional examples of de novo autoimmune-like hepatitis following allo-SCT in which the target liver cells and effector cells are different in origin (Table 1) . [2] [3] [4] [5] 8, 9 Habib et al. used the term 'alloimmune hepatitis' to describe this entity. The laboratory and histological findings and clinical course of our patient were very similar to these cases and she may be included in the same disease entity. As our patient and her donor were sex matched, we could not confirm the donor origin of immune-reactive cells, which was demonstrated by in situ hybridization in the patient reported by Habib et al., Mullighan et al. report Moderate number of eosinophils were observed. (c) High magnification ( Â 400, HE staining). Lobular inflammation was modest and marked hepatocyte swelling (ballooning degeneration) was observed. Immunostaining revealed that cells infiltrating portal areas were predominantly CD20 þ lymphocytes (d) and CD138 þ plasma cells (e), and interlobular bile ducts are rather preserved (f, g). CD8 þ T-cells are much less than GVHD or viral infections (h). These findings were rather more consistent with that of autoimmune-like hepatitis than with classical hepatic GVHD. CD20 þ B-lymphocytes were not observed at all after rituximab treatment (i). ALT, alanine transaminase; AST, aspartate aminotransferase; MMF, mycophenolate mofetil; mPSL, methyl predonisolone; PSL, predonisolone; RTX, rituximab. 2 and the other case died during evaluation for liver transplantation. 5 Rituximab, a human-mouse chimeric MoAb against CD20 B-lymphocytes, has been reported to be effective in several cases of AIH. 6, 7 Based on these reports, we treated this patient with four courses of rituximab. Sequential immunohistochemical studies proved that CD20 þ B-cell and CD138 þ plasmacytes had completely disappeared after rituximab administration, consistent with the observed improvement in clinical manifestations. Rituximab therapy could be a promising candidate for treatments of autoimmune-like hepatitis after allo-SCT.
